Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 4/20 | 0.59 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | CTRC | Q99895 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000844 | 1.00 | GSK3B (0.59) | GSK3BKDRTLK2MAPTMAPK1 | |
| SCHEMBL7812245 | 0.81 | LRRK2 (0.56) | RETEGFRPDGFRBRPS6KA3LRRK2 | |
| SCHEMBL7812244 | 0.81 | LRRK2 (0.56) | RETEGFRPDGFRBRPS6KA3LRRK2 | |
| SCHEMBL24152544 | 0.79 | TLK2 (0.44) | GSK3BKDRTLK2KMT2ARET | |
| SCHEMBL5999765 | 0.78 | GSK3B (0.54) | GSK3BKDRTLK2MAPTMAPK1 | |
| SCHEMBL5999763 | 0.78 | GSK3B (0.54) | GSK3BKDRTLK2MAPTMAPK1 | |
| SCHEMBL12013784 | 0.77 | MAPT (0.45) | MAPTGAAKMT2ATDP1 | |
| SCHEMBL6001044 | 0.75 | MAPT (0.59) | GSK3BKDRTLK2MAPTMAPK1 | |
| SCHEMBL6001045 | 0.75 | MAPT (0.59) | GSK3BKDRTLK2MAPTMAPK1 | |
| SCHEMBL13036886 | 0.75 | GSK3B (1.00) | GSK3BKDRTLK2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101371820-B | Anticancer sustained-release agent containing methotrexate potentiating agent | Jinan shuaihua medicine science and technology co ltd | 2010-06-02 | — | — | CN | disclosed |
| CN-101548948-A | Anti-cancer medicine sustained-release agent containing 5-FU potentiating agent | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2009-10-07 | — | — | CN | disclosed |
| CN-100531717-C | Anticancer sustained-release agent containing methotrexate synergist | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2009-08-26 | — | — | CN | disclosed |
| CN-101385698-A | Anti-cancer sustained-released implantation agent | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2009-03-18 | — | — | CN | disclosed |
| CN-101380296-A | Anticancer sustained-release formulation loaded with platinum compound and synergist thereof | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2009-03-11 | — | — | CN | disclosed |
| CN-101371820-A | Anticancer sustained-release agent containing methotrexate potentiating agent | JINAN SHUAIHUA MEDICINE SCIENC (CN) | 2009-02-25 | — | — | CN | disclosed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| CN-1850040-A | Loaded platinum drug and its synergist anticancer drug slow release agent | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2006-10-25 | — | — | CN | disclosed |
| CN-1846682-A | Anticancer sustained-release agent containing methotrexate synergist | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | disclosed |
| CN-1846688-A | Anticancer drug sustained release agent loaded with taxane and synergist thereof | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | disclosed |
| US-6225335-B1 | MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | GSK3B 972/4885KDR 3609/4885TLK2 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.